Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study

NCT05169151 | Withdrawn

• 2 other identifiers: 2020-1048NCI-2021-10994
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This study attempts to learn more about the activity levels of adolescent and young adult (AYA) cancer patients or survivors at risk for cardiovascular morbidity and frailty by using a smartphone application called Beiwe. Collecting activity level data on AYA cancer patients or survivors may help patients achieve better quality of life.

Conditions

Central Nervous System Neoplasm; Hodgkin Lymphoma; Malignant Solid Neoplasm; Non-Hodgkin Lymphoma; Sarcoma

Outcome Measures

Primary Outcomes (1)

• To characterize patient mobility over time.

  Will be analyzed by linear mixed-effect models with relation to time point (30, 60, 90, 120, 150, and 180 days), blocking on patient, with differences among time points assessed by Tukey-adjusted contrasts.

  Through study completion, an average of 1 year

Study Arms (1)

Observational (physical activity tracking)

Patients utilize smartphone application to monitor physical activity and mobility up to 180 days during treatment or post-treatment.

Other: Smartphone Application

Interventions

Smartphone Application OTHER

Utilize smartphone application

Also known as: App, Smartphone App

Observational (physical activity tracking)

Eligibility Criteria

• Age: 15 Years - 39 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Adolescent and young adults with cancer who are at risk for developing cardiovascular disease and/or frailty and are within 3 weeks of starting anti-cancer therapy.

You may qualify if:

• Patients age 15-39 at the time of study entry
• Patients must be within 3 weeks of starting anti-cancer therapy
• Patients must have a diagnosis of Hodgkin lymphoma, non-Hodgkin lymphoma, sarcoma and have plans to receive anthracyclines or radiation therapy to the chest OR
• have a diagnosis of a central nervous system (CNS) tumor OR
• have plans to receive a stem cell transplant
• Patients must have smartphone device and regular access to internet
• Patients must be English-speaking

You may not qualify if:

• Patients that are a ward of the state

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

M D Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

• M.D. Anderson Cancer Center

MeSH Terms

Conditions

Central Nervous System Neoplasms; Hodgkin Disease; Lymphoma, Non-Hodgkin; Sarcoma

Interventions

Amyloid

Condition Hierarchy (Ancestors)

Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Nervous System Diseases; Lymphoma; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Neoplasms, Connective and Soft Tissue

Intervention Hierarchy (Ancestors)

Multiprotein Complexes; Macromolecular Substances; Proteins; Amino Acids, Peptides, and Proteins

Study Officials

• Michael Roth, MD

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 9, 2021
• First Posted: December 23, 2021
• Study Start: February 17, 2022
• Primary Completion: April 18, 2023
• Study Completion: April 18, 2023
• Last Updated: April 24, 2023

Record last verified: 2023-04

Locations

US (1)